GlassScriptPhysician profile
Susan S Cain
NPI 1033227863
$8,136.03
in general payments reported to CMS, 2019-2025
32 companies · $3,236 in 2025
The $3,236 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $1,037 · 2023: $1,116 · 2024: $2,092 · 2025: $3,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,931 · Education: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,931.22 |
| Education | $512.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $2,018.56 | 2021-2025 | Provenge |
| Janssen Biotech, INC. | $1,560.75 | 2021-2025 | Erleada, Rybrevant, Carvykti |
| Astellas Pharma US INC | $944.12 | 2021-2025 | Xtandi, Myrbetriq |
| Ferring Pharmaceuticals INC. | $642.61 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $616.21 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $577.44 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $398.02 | 2021-2025 | |
| Accord Healthcare, INC. | $135.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.69 | 2022 | |
| Pfizer INC. | $120.09 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $114.07 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $95.50 | 2021-2023 | Xiaflex |
| Allergan, INC. | $83.17 | 2021-2022 | |
| Foundation Medicine, INC. | $81.42 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $79.58 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $68.76 | 2022 | |
| Rochester Medical Corporation | $68.22 | 2022 | |
| Coloplast Corp | $66.54 | 2021 | |
| Janssen Scientific Affairs, LLC | $54.13 | 2024 | Erleada |
| Myovant Sciences INC. | $49.56 | 2021-2022 | |
| Endo USA, INC. | $44.21 | 2024 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $33.31 | 2023-2025 | Keytruda, Lynparza |
| Telix Pharmaceuticals | $19.86 | 2025 | Illuccix |
| Progenics Pharmaceuticals, INC. | $19.76 | 2025 | |
| Axonics, INC. | $19.40 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.31 | 2024 | |
| Olympus America INC. | $15.08 | 2022 | |
| Medtronic, INC. | $14.62 | 2021 | |
| Hollister Incorporated | $14.27 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.02 | 2021 | |
| Blue Earth Diagnostics | $12.35 | 2021 | |
| Urogen Pharma, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.